FDA approves King's 'abuse-resistant' painkiller

Shares of King Pharmaceuticals surged on the news that the FDA has approved Embeda, a new painkiller that's designed to limit abuse by people looking for a quick high. King researchers added an ingredient to Embeda that is supposed to interfere with the body's absorption of morphine when the therapy is abused. But there's a catch: Neither the FDA nor King say that there's convincing data that shows the painkiller actually works in frustrating morphine abuse. King is one of several developers working to develop new painkillers that thwart addicts. Conclusive data that one of the therapies can actually prevent abuse is likely to be rewarded with a big share of the market. Report

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.